Sustained Release Hormone Suspension for Menopausal Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormonal replacement therapies for menopause symptoms are associated with increased risks of uterine and breast cancers, and existing treatments often require daily administration, leading to non-compliance due to inconvenience.
Innovation Solution
A parenteral pharmaceutical formulation in suspension form, providing sustained release of low and ultra-low doses of estradiol and progesterone via intramuscular injection, using micro-particles of specific sizes, combined with surfactants, isosmotic agents, viscosity modifiers, and preservatives to maintain stability and efficacy for monthly administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard dose hormonal replacement therapy is used, then menopausal symptoms are effectively treated, but the risk of uterine and breast cancers increases
Solution Approach 1:
The patent applies parameter changes by reducing the hormonal dosage from standard levels to low and ultra-low doses (1mg estradiol and 20mg progesterone, or 0.5mg estradiol and 15mg progesterone per month). This dosage reduction directly addresses the contradiction by maintaining therapeutic effectiveness for menopausal symptoms while significantly lowering the carcinogenic risk associated with standard dose hormonal replacement therapy.
2Reliability
If daily administration of hormonal therapy is required, then therapeutic effectiveness is maintained, but patient compliance decreases due to inconvenience
Solution Approach 1:
The patent implements periodic action by formulating the hormonal composition for sustained release over monthly intervals through intramuscular injection. This allows the therapy to be administered once monthly rather than daily, significantly improving patient compliance and ease of operation while maintaining continuous therapeutic effectiveness through the sustained release mechanism.
3Object-affected harmful factors
If low and ultra-low doses of hormones are used, then the risk of cancer is reduced, but the effectiveness in treating severe menopausal symptoms may be compromised
Solution Approach 1:
The patent optimizes the parameter of hormonal dosage by establishing specific low and ultra-low dose regimens (1mg estradiol and 20mg progesterone, or 0.5mg estradiol and 15mg progesterone per month). Clinical evaluation demonstrated that these reduced doses maintain sufficient effectiveness for treating menopausal symptoms including hot flashes and vaginal dryness while achieving the primary goal of reducing cancer risk.
4Ease of operation
If monthly intramuscular injection is used, then patient compliance improves, but the complexity of administration increases compared to oral therapy
Solution Approach 1:
The patent accepts the increased administration complexity of intramuscular injection as a necessary trade-off to achieve monthly periodic administration. The sustained release formulation enables the hormone to be delivered once monthly, which significantly improves patient compliance compared to daily oral therapy. The complexity is minimized by using a single injection rather than multiple administrations within the monthly interval.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Parenteral pharmaceutical formulation or composition, in suspension, having sustained release, containing suspended particles of estradiol and progesterone for hormonal replacement in female mammals in low and ultralow dosage; the formulation consists of an injectable suspension comprising particles of estradiol, particles of progesterone, a surfactant agent, an isosmotic agent, a thickening agent, and one or more preservation agents, wherein the estradiol is in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns, for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.